睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07475026,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Men with partners of childbearing potential must agree to use effective contraception during the study and for 6 months after the end of study treatment.

    入选标准第 25 条

  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.

    入选标准第 3 条

  4. Absolute neutrophil count (ANC) ≥ 1,500/mm³

    入选标准第 11 条

    Platelet count ≥ 100,000/mm³

    入选标准第 12 条

    Hemoglobin ≥ 5.6 mmol/L (9 g/dL)

    入选标准第 13 条

    Serum creatinine (SCr) ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)

    入选标准第 15 条

    Total bilirubin (TBIL) ≤ 1.5 × ULN

    入选标准第 16 条

    AST and/or ALT ≤ 2.5 × ULN

    入选标准第 17 条

    International normalized ratio (INR) ≤ 1.5 × ULN

    入选标准第 20 条

    Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN

    入选标准第 21 条

    Prothrombin time (PT) ≤ 1.5 × ULN

    入选标准第 22 条

  5. At least one measurable lesion per RECIST v1.1.

    入选标准第 7 条

  6. Known cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular-cholangiocarcinoma, or fibrolamellar carcinoma; or any other active malignancy besides HCC within the past 5 years or concurrently (except cured basal cell carcinoma of the skin and cervical carcinoma in situ).

    排除标准第 2 条

    Congenital or acquired immunodeficiency, such as HIV infection.

    排除标准第 17 条

  7. Women of childbearing potential must agree to use effective contraception (e.g., intrauterine device, oral contraceptives, or condoms) during study treatment and for 6 months after the last dose; must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.

    入选标准第 24 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07475026,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily participates in this study and provides written informed consent.
  2. Aged 18 to 75 years, inclusive; male or female.
  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.
  4. Child-Pugh class A liver function.
  5. China Liver Cancer (CNLC) stage Ib to IIa.
  6. Histologically/cytologically confirmed HCC, or clinically diagnosed primary hepatocellular carcinoma according to accepted diagnostic criteria, with lesions meeting the criteria for surgical resection as defined in the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2024 edition).
  7. At least one measurable lesion per RECIST v1.1.
  8. Estimated life expectancy ≥ 6 months.
  9. Adequate major organ function as defined below, without transfusion of any blood components or use of hematopoietic growth factors within 14 days prior to assessment:
  10. Hematology
  11. Absolute neutrophil count (ANC) ≥ 1,500/mm³
  12. Platelet count ≥ 100,000/mm³
  13. Hemoglobin ≥ 5.6 mmol/L (9 g/dL)
  14. Hepatic and renal function
  15. Serum creatinine (SCr) ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula)
  16. Total bilirubin (TBIL) ≤ 1.5 × ULN
  17. AST and/or ALT ≤ 2.5 × ULN
  18. Urine protein < 2+; if urine protein is ≥ 2+, 24-hour urine protein must be ≤ 1 g.
  19. Adequate coagulation function, with no active bleeding and no thrombotic disease:
  20. International normalized ratio (INR) ≤ 1.5 × ULN
  21. Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
  22. Prothrombin time (PT) ≤ 1.5 × ULN
  23. Contraception requirements:
  24. Women of childbearing potential must agree to use effective contraception (e.g., intrauterine device, oral contraceptives, or condoms) during study treatment and for 6 months after the last dose; must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.
  25. Men with partners of childbearing potential must agree to use effective contraception during the study and for 6 months after the end of study treatment.
  26. Demonstrates good compliance and is able/willing to complete required follow-up.

排除标准:Exclusion Criteria:

  1. Prior antitumor therapy for the current HCC, including radiotherapy, chemotherapy, concurrent chemoradiotherapy, other locoregional therapies (e.g., TACE, HAIC), or prior immunotherapy or targeted therapy.
  2. Known cholangiocarcinoma, sarcomatoid HCC, mixed hepatocellular-cholangiocarcinoma, or fibrolamellar carcinoma; or any other active malignancy besides HCC within the past 5 years or concurrently (except cured basal cell carcinoma of the skin and cervical carcinoma in situ).
  3. Hypertension inadequately controlled with antihypertensive therapy (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg); or history of hypertensive crisis or hypertensive encephalopathy.
  4. Known hypersensitivity to macromolecular protein preparations, or known allergy to tislelizumab, lenvatinib, or any of their excipients.
  5. Any active autoimmune disease or history of autoimmune disease (including but not limited to autoimmune hepatitis, interstitial pneumonitis, uveitis, enteritis/colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism). Patients with vitiligo, or asthma that completely resolved in childhood and requires no intervention in adulthood, may be eligible. Patients with asthma requiring medical intervention with bronchodilators are not eligible.
  6. Use of immunosuppressive agents or systemic, or absorbable topical, corticosteroids for immunosuppressive purposes (dose >10 mg/day prednisone or equivalent) within 2 weeks prior to enrollment.
  7. Symptomatic ascites or pleural effusion requiring therapeutic paracentesis or drainage.
  8. Uncontrolled clinically significant cardiac symptoms or disease, including any of the following:
  9. New York Heart Association (NYHA) class > II heart failure
  10. Unstable angina
  11. Myocardial infarction within 1 year
  12. Clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention
  13. Within the past 3 months, presence of gastrointestinal conditions such as esophageal varices, active gastric or duodenal ulcer, ulcerative colitis, portal hypertension, or active bleeding from an unresected tumor; or any other condition judged by the investigator to confer a risk of gastrointestinal bleeding or perforation.
  14. History of or current severe bleeding (within 3 months, bleeding volume >30 mL), hemoptysis (within 4 weeks, >5 mL fresh blood), or thromboembolic events within 12 months (including stroke and/or transient ischemic attack).
  15. Active infection, or unexplained fever >38.5°C during screening or prior to first dose (fever judged by the investigator to be tumor-related is allowed).
  16. Objective evidence of prior or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severely impaired pulmonary function.
  17. Congenital or acquired immunodeficiency, such as HIV infection.
  18. Receipt of a live vaccine within 4 weeks prior to study drug administration, or anticipated need for live vaccination during the study.
  19. Known history of psychotropic drug abuse, alcoholism, or illicit drug use.
  20. Anticipated inability or unwillingness to comply with required study procedures, assessments, and follow-up (including completion of standard-of-care evaluations not covered by the study), as judged by the investigator.
  21. Any other condition that, in the investigator's judgment, makes the subject unsuitable for the study, including factors that may lead to premature study discontinuation (e.g., other serious diseases [including psychiatric disorders] requiring concomitant treatment, severe laboratory abnormalities, or family/social factors that may compromise subject safety or the collection of data and specimens).

引自 ClinicalTrials.gov, NCT07475026, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07475026,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07475026